Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG2512 in Advanced Solid Tumors
NCT07348653Phase 1Recruiting
- Sponsor
- Maijin Biomedical Technology
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MG2512 in solid tumor, sponsored by Maijin Biomedical Technology. Primary endpoints: Dose limiting toxicity at 3 weeks, Maximum tolerated dose at 3 weeks and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
MG2512
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07348653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348653.